Suppression of VM might prevent metastasis to the liver and brain, both of which are frequent metastatic sites for HER2+ breast cancer [41], and thereby improve the prognosis of patients with advanced and metastatic HER2+ breast cancer. This evidence concerns the gene ERBB2 and breast cancer.